nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—MTOR—liver cancer	0.482	0.847	CbGaD
Tacrolimus—ALB—liver cancer	0.0869	0.153	CbGaD
Tacrolimus—CYP3A7-CYP3A51P—Sorafenib—liver cancer	0.037	0.25	CbGbCtD
Tacrolimus—CYP3A7—Sorafenib—liver cancer	0.037	0.25	CbGbCtD
Tacrolimus—CYP3A5—Sorafenib—liver cancer	0.0277	0.187	CbGbCtD
Tacrolimus—ABCB1—Sorafenib—liver cancer	0.0181	0.122	CbGbCtD
Tacrolimus—ABCB1—Doxorubicin—liver cancer	0.011	0.074	CbGbCtD
Tacrolimus—CYP3A4—Sorafenib—liver cancer	0.0108	0.0731	CbGbCtD
Tacrolimus—CYP3A4—Doxorubicin—liver cancer	0.00656	0.0443	CbGbCtD
Tacrolimus—ORM1—bile—liver cancer	0.00469	0.342	CbGeAlD
Tacrolimus—Everolimus—MTOR—liver cancer	0.00188	0.306	CrCbGaD
Tacrolimus—Pimecrolimus—MTOR—liver cancer	0.00188	0.306	CrCbGaD
Tacrolimus—ORM1—gall bladder—liver cancer	0.0013	0.0949	CbGeAlD
Tacrolimus—Temsirolimus—MTOR—liver cancer	0.00127	0.207	CrCbGaD
Tacrolimus—MTOR—embryo—liver cancer	0.00117	0.0855	CbGeAlD
Tacrolimus—ALB—gall bladder—liver cancer	0.00114	0.0832	CbGeAlD
Tacrolimus—Sirolimus—MTOR—liver cancer	0.00112	0.182	CrCbGaD
Tacrolimus—ABCA5—liver—liver cancer	0.00109	0.0792	CbGeAlD
Tacrolimus—PPP3CA—liver—liver cancer	0.000733	0.0535	CbGeAlD
Tacrolimus—CYP3A7—liver—liver cancer	0.000603	0.044	CbGeAlD
Tacrolimus—MTOR—liver—liver cancer	0.000541	0.0395	CbGeAlD
Tacrolimus—CYP3A7-CYP3A51P—liver—liver cancer	0.000512	0.0374	CbGeAlD
Tacrolimus—FKBP1A—liver—liver cancer	0.000487	0.0356	CbGeAlD
Tacrolimus—ORM1—liver—liver cancer	0.000381	0.0278	CbGeAlD
Tacrolimus—ALB—liver—liver cancer	0.000334	0.0244	CbGeAlD
Tacrolimus—ABCB1—embryo—liver cancer	0.000244	0.0178	CbGeAlD
Tacrolimus—CYP3A5—liver—liver cancer	0.000212	0.0155	CbGeAlD
Tacrolimus—CYP3A4—liver—liver cancer	0.000159	0.0116	CbGeAlD
Tacrolimus—ABCB1—liver—liver cancer	0.000113	0.00822	CbGeAlD
Tacrolimus—Dry skin—Doxorubicin—liver cancer	0.000107	0.00069	CcSEcCtD
Tacrolimus—Pancreatitis—Epirubicin—liver cancer	0.000107	0.000689	CcSEcCtD
Tacrolimus—Vomiting—Sorafenib—liver cancer	0.000106	0.000688	CcSEcCtD
Tacrolimus—Orthostatic hypotension—Doxorubicin—liver cancer	0.000106	0.000687	CcSEcCtD
Tacrolimus—Hypokalaemia—Doxorubicin—liver cancer	0.000106	0.000685	CcSEcCtD
Tacrolimus—Angina pectoris—Epirubicin—liver cancer	0.000106	0.000685	CcSEcCtD
Tacrolimus—Rash—Sorafenib—liver cancer	0.000105	0.000682	CcSEcCtD
Tacrolimus—Dermatitis—Sorafenib—liver cancer	0.000105	0.000681	CcSEcCtD
Tacrolimus—Breast disorder—Doxorubicin—liver cancer	0.000105	0.00068	CcSEcCtD
Tacrolimus—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000105	0.000678	CcSEcCtD
Tacrolimus—Headache—Sorafenib—liver cancer	0.000105	0.000678	CcSEcCtD
Tacrolimus—Bronchitis—Epirubicin—liver cancer	0.000105	0.000676	CcSEcCtD
Tacrolimus—Pancytopenia—Epirubicin—liver cancer	0.000103	0.000668	CcSEcCtD
Tacrolimus—Gastritis—Doxorubicin—liver cancer	0.000103	0.000666	CcSEcCtD
Tacrolimus—Muscular weakness—Doxorubicin—liver cancer	0.000103	0.000664	CcSEcCtD
Tacrolimus—Dysuria—Epirubicin—liver cancer	0.000102	0.000657	CcSEcCtD
Tacrolimus—Neutropenia—Epirubicin—liver cancer	0.000102	0.000657	CcSEcCtD
Tacrolimus—Abdominal distension—Doxorubicin—liver cancer	0.000101	0.000655	CcSEcCtD
Tacrolimus—Asthma—Doxorubicin—liver cancer	0.000101	0.00065	CcSEcCtD
Tacrolimus—Influenza—Doxorubicin—liver cancer	0.000101	0.00065	CcSEcCtD
Tacrolimus—Dysphagia—Doxorubicin—liver cancer	0.000101	0.00065	CcSEcCtD
Tacrolimus—Pollakiuria—Epirubicin—liver cancer	0.0001	0.000649	CcSEcCtD
Tacrolimus—Nausea—Sorafenib—liver cancer	9.93e-05	0.000643	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Epirubicin—liver cancer	9.92e-05	0.000642	CcSEcCtD
Tacrolimus—Weight increased—Epirubicin—liver cancer	9.89e-05	0.00064	CcSEcCtD
Tacrolimus—Pancreatitis—Doxorubicin—liver cancer	9.86e-05	0.000638	CcSEcCtD
Tacrolimus—Weight decreased—Epirubicin—liver cancer	9.83e-05	0.000636	CcSEcCtD
Tacrolimus—Hyperglycaemia—Epirubicin—liver cancer	9.81e-05	0.000634	CcSEcCtD
Tacrolimus—Angina pectoris—Doxorubicin—liver cancer	9.8e-05	0.000634	CcSEcCtD
Tacrolimus—Pneumonia—Epirubicin—liver cancer	9.75e-05	0.00063	CcSEcCtD
Tacrolimus—Infestation NOS—Epirubicin—liver cancer	9.69e-05	0.000627	CcSEcCtD
Tacrolimus—Infestation—Epirubicin—liver cancer	9.69e-05	0.000627	CcSEcCtD
Tacrolimus—Bronchitis—Doxorubicin—liver cancer	9.67e-05	0.000626	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Epirubicin—liver cancer	9.61e-05	0.000621	CcSEcCtD
Tacrolimus—Pancytopenia—Doxorubicin—liver cancer	9.55e-05	0.000618	CcSEcCtD
Tacrolimus—Renal failure—Epirubicin—liver cancer	9.53e-05	0.000616	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Epirubicin—liver cancer	9.5e-05	0.000614	CcSEcCtD
Tacrolimus—Stomatitis—Epirubicin—liver cancer	9.45e-05	0.000611	CcSEcCtD
Tacrolimus—Jaundice—Epirubicin—liver cancer	9.45e-05	0.000611	CcSEcCtD
Tacrolimus—Urinary tract infection—Epirubicin—liver cancer	9.42e-05	0.000609	CcSEcCtD
Tacrolimus—Conjunctivitis—Epirubicin—liver cancer	9.42e-05	0.000609	CcSEcCtD
Tacrolimus—Dysuria—Doxorubicin—liver cancer	9.4e-05	0.000608	CcSEcCtD
Tacrolimus—Neutropenia—Doxorubicin—liver cancer	9.4e-05	0.000608	CcSEcCtD
Tacrolimus—Sweating—Epirubicin—liver cancer	9.29e-05	0.000601	CcSEcCtD
Tacrolimus—Pollakiuria—Doxorubicin—liver cancer	9.29e-05	0.000601	CcSEcCtD
Tacrolimus—Haematuria—Epirubicin—liver cancer	9.24e-05	0.000598	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Doxorubicin—liver cancer	9.18e-05	0.000594	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Epirubicin—liver cancer	9.17e-05	0.000593	CcSEcCtD
Tacrolimus—Weight increased—Doxorubicin—liver cancer	9.15e-05	0.000592	CcSEcCtD
Tacrolimus—Epistaxis—Epirubicin—liver cancer	9.14e-05	0.000591	CcSEcCtD
Tacrolimus—Weight decreased—Doxorubicin—liver cancer	9.1e-05	0.000588	CcSEcCtD
Tacrolimus—Sinusitis—Epirubicin—liver cancer	9.09e-05	0.000588	CcSEcCtD
Tacrolimus—Hyperglycaemia—Doxorubicin—liver cancer	9.07e-05	0.000587	CcSEcCtD
Tacrolimus—Agranulocytosis—Epirubicin—liver cancer	9.04e-05	0.000585	CcSEcCtD
Tacrolimus—Pneumonia—Doxorubicin—liver cancer	9.02e-05	0.000583	CcSEcCtD
Tacrolimus—Infestation—Doxorubicin—liver cancer	8.97e-05	0.00058	CcSEcCtD
Tacrolimus—Infestation NOS—Doxorubicin—liver cancer	8.97e-05	0.00058	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Doxorubicin—liver cancer	8.89e-05	0.000575	CcSEcCtD
Tacrolimus—Bradycardia—Epirubicin—liver cancer	8.86e-05	0.000573	CcSEcCtD
Tacrolimus—Renal failure—Doxorubicin—liver cancer	8.82e-05	0.00057	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Doxorubicin—liver cancer	8.79e-05	0.000569	CcSEcCtD
Tacrolimus—Haemoglobin—Epirubicin—liver cancer	8.74e-05	0.000566	CcSEcCtD
Tacrolimus—Stomatitis—Doxorubicin—liver cancer	8.74e-05	0.000565	CcSEcCtD
Tacrolimus—Jaundice—Doxorubicin—liver cancer	8.74e-05	0.000565	CcSEcCtD
Tacrolimus—Rhinitis—Epirubicin—liver cancer	8.72e-05	0.000564	CcSEcCtD
Tacrolimus—Urinary tract infection—Doxorubicin—liver cancer	8.72e-05	0.000564	CcSEcCtD
Tacrolimus—Conjunctivitis—Doxorubicin—liver cancer	8.72e-05	0.000564	CcSEcCtD
Tacrolimus—Haemorrhage—Epirubicin—liver cancer	8.7e-05	0.000563	CcSEcCtD
Tacrolimus—Hepatitis—Epirubicin—liver cancer	8.7e-05	0.000563	CcSEcCtD
Tacrolimus—Hypoaesthesia—Epirubicin—liver cancer	8.66e-05	0.00056	CcSEcCtD
Tacrolimus—Pharyngitis—Epirubicin—liver cancer	8.64e-05	0.000558	CcSEcCtD
Tacrolimus—Sweating—Doxorubicin—liver cancer	8.6e-05	0.000556	CcSEcCtD
Tacrolimus—Urinary tract disorder—Epirubicin—liver cancer	8.59e-05	0.000556	CcSEcCtD
Tacrolimus—Oedema peripheral—Epirubicin—liver cancer	8.57e-05	0.000554	CcSEcCtD
Tacrolimus—Haematuria—Doxorubicin—liver cancer	8.55e-05	0.000553	CcSEcCtD
Tacrolimus—Connective tissue disorder—Epirubicin—liver cancer	8.55e-05	0.000553	CcSEcCtD
Tacrolimus—Urethral disorder—Epirubicin—liver cancer	8.53e-05	0.000552	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Doxorubicin—liver cancer	8.48e-05	0.000549	CcSEcCtD
Tacrolimus—Epistaxis—Doxorubicin—liver cancer	8.46e-05	0.000547	CcSEcCtD
Tacrolimus—Sinusitis—Doxorubicin—liver cancer	8.41e-05	0.000544	CcSEcCtD
Tacrolimus—Visual impairment—Epirubicin—liver cancer	8.38e-05	0.000542	CcSEcCtD
Tacrolimus—Agranulocytosis—Doxorubicin—liver cancer	8.37e-05	0.000541	CcSEcCtD
Tacrolimus—Erythema multiforme—Epirubicin—liver cancer	8.23e-05	0.000532	CcSEcCtD
Tacrolimus—Bradycardia—Doxorubicin—liver cancer	8.2e-05	0.00053	CcSEcCtD
Tacrolimus—Eye disorder—Epirubicin—liver cancer	8.13e-05	0.000526	CcSEcCtD
Tacrolimus—Tinnitus—Epirubicin—liver cancer	8.11e-05	0.000525	CcSEcCtD
Tacrolimus—Haemoglobin—Doxorubicin—liver cancer	8.09e-05	0.000523	CcSEcCtD
Tacrolimus—Cardiac disorder—Epirubicin—liver cancer	8.07e-05	0.000522	CcSEcCtD
Tacrolimus—Flushing—Epirubicin—liver cancer	8.07e-05	0.000522	CcSEcCtD
Tacrolimus—Rhinitis—Doxorubicin—liver cancer	8.07e-05	0.000522	CcSEcCtD
Tacrolimus—Haemorrhage—Doxorubicin—liver cancer	8.05e-05	0.000521	CcSEcCtD
Tacrolimus—Hepatitis—Doxorubicin—liver cancer	8.05e-05	0.000521	CcSEcCtD
Tacrolimus—Hypoaesthesia—Doxorubicin—liver cancer	8.01e-05	0.000518	CcSEcCtD
Tacrolimus—Pharyngitis—Doxorubicin—liver cancer	7.99e-05	0.000517	CcSEcCtD
Tacrolimus—Urinary tract disorder—Doxorubicin—liver cancer	7.95e-05	0.000514	CcSEcCtD
Tacrolimus—Oedema peripheral—Doxorubicin—liver cancer	7.93e-05	0.000513	CcSEcCtD
Tacrolimus—Connective tissue disorder—Doxorubicin—liver cancer	7.91e-05	0.000512	CcSEcCtD
Tacrolimus—Angiopathy—Epirubicin—liver cancer	7.89e-05	0.000511	CcSEcCtD
Tacrolimus—Urethral disorder—Doxorubicin—liver cancer	7.89e-05	0.00051	CcSEcCtD
Tacrolimus—Immune system disorder—Epirubicin—liver cancer	7.86e-05	0.000508	CcSEcCtD
Tacrolimus—Mediastinal disorder—Epirubicin—liver cancer	7.84e-05	0.000507	CcSEcCtD
Tacrolimus—Chills—Epirubicin—liver cancer	7.81e-05	0.000505	CcSEcCtD
Tacrolimus—Arrhythmia—Epirubicin—liver cancer	7.77e-05	0.000503	CcSEcCtD
Tacrolimus—Visual impairment—Doxorubicin—liver cancer	7.76e-05	0.000502	CcSEcCtD
Tacrolimus—Alopecia—Epirubicin—liver cancer	7.69e-05	0.000497	CcSEcCtD
Tacrolimus—Mental disorder—Epirubicin—liver cancer	7.62e-05	0.000493	CcSEcCtD
Tacrolimus—Erythema multiforme—Doxorubicin—liver cancer	7.61e-05	0.000492	CcSEcCtD
Tacrolimus—Erythema—Epirubicin—liver cancer	7.57e-05	0.00049	CcSEcCtD
Tacrolimus—Malnutrition—Epirubicin—liver cancer	7.57e-05	0.00049	CcSEcCtD
Tacrolimus—Eye disorder—Doxorubicin—liver cancer	7.52e-05	0.000487	CcSEcCtD
Tacrolimus—Tinnitus—Doxorubicin—liver cancer	7.51e-05	0.000485	CcSEcCtD
Tacrolimus—Flushing—Doxorubicin—liver cancer	7.47e-05	0.000483	CcSEcCtD
Tacrolimus—Cardiac disorder—Doxorubicin—liver cancer	7.47e-05	0.000483	CcSEcCtD
Tacrolimus—Flatulence—Epirubicin—liver cancer	7.46e-05	0.000483	CcSEcCtD
Tacrolimus—Tension—Epirubicin—liver cancer	7.43e-05	0.000481	CcSEcCtD
Tacrolimus—Dysgeusia—Epirubicin—liver cancer	7.42e-05	0.00048	CcSEcCtD
Tacrolimus—Nervousness—Epirubicin—liver cancer	7.36e-05	0.000476	CcSEcCtD
Tacrolimus—Back pain—Epirubicin—liver cancer	7.33e-05	0.000474	CcSEcCtD
Tacrolimus—Angiopathy—Doxorubicin—liver cancer	7.3e-05	0.000472	CcSEcCtD
Tacrolimus—Muscle spasms—Epirubicin—liver cancer	7.28e-05	0.000471	CcSEcCtD
Tacrolimus—Immune system disorder—Doxorubicin—liver cancer	7.27e-05	0.00047	CcSEcCtD
Tacrolimus—Mediastinal disorder—Doxorubicin—liver cancer	7.26e-05	0.000469	CcSEcCtD
Tacrolimus—Chills—Doxorubicin—liver cancer	7.22e-05	0.000467	CcSEcCtD
Tacrolimus—Arrhythmia—Doxorubicin—liver cancer	7.19e-05	0.000465	CcSEcCtD
Tacrolimus—Vision blurred—Epirubicin—liver cancer	7.14e-05	0.000462	CcSEcCtD
Tacrolimus—Alopecia—Doxorubicin—liver cancer	7.11e-05	0.00046	CcSEcCtD
Tacrolimus—Mental disorder—Doxorubicin—liver cancer	7.05e-05	0.000456	CcSEcCtD
Tacrolimus—Ill-defined disorder—Epirubicin—liver cancer	7.03e-05	0.000454	CcSEcCtD
Tacrolimus—Erythema—Doxorubicin—liver cancer	7.01e-05	0.000453	CcSEcCtD
Tacrolimus—Malnutrition—Doxorubicin—liver cancer	7.01e-05	0.000453	CcSEcCtD
Tacrolimus—Anaemia—Epirubicin—liver cancer	7e-05	0.000453	CcSEcCtD
Tacrolimus—Agitation—Epirubicin—liver cancer	6.96e-05	0.00045	CcSEcCtD
Tacrolimus—Flatulence—Doxorubicin—liver cancer	6.91e-05	0.000447	CcSEcCtD
Tacrolimus—Tension—Doxorubicin—liver cancer	6.88e-05	0.000445	CcSEcCtD
Tacrolimus—Dysgeusia—Doxorubicin—liver cancer	6.86e-05	0.000444	CcSEcCtD
Tacrolimus—Malaise—Epirubicin—liver cancer	6.83e-05	0.000442	CcSEcCtD
Tacrolimus—Nervousness—Doxorubicin—liver cancer	6.81e-05	0.00044	CcSEcCtD
Tacrolimus—Vertigo—Epirubicin—liver cancer	6.8e-05	0.00044	CcSEcCtD
Tacrolimus—Syncope—Epirubicin—liver cancer	6.79e-05	0.000439	CcSEcCtD
Tacrolimus—Leukopenia—Epirubicin—liver cancer	6.78e-05	0.000438	CcSEcCtD
Tacrolimus—Back pain—Doxorubicin—liver cancer	6.78e-05	0.000438	CcSEcCtD
Tacrolimus—Muscle spasms—Doxorubicin—liver cancer	6.74e-05	0.000436	CcSEcCtD
Tacrolimus—Palpitations—Epirubicin—liver cancer	6.69e-05	0.000433	CcSEcCtD
Tacrolimus—Loss of consciousness—Epirubicin—liver cancer	6.66e-05	0.000431	CcSEcCtD
Tacrolimus—Cough—Epirubicin—liver cancer	6.61e-05	0.000427	CcSEcCtD
Tacrolimus—Vision blurred—Doxorubicin—liver cancer	6.6e-05	0.000427	CcSEcCtD
Tacrolimus—Convulsion—Epirubicin—liver cancer	6.56e-05	0.000424	CcSEcCtD
Tacrolimus—Hypertension—Epirubicin—liver cancer	6.54e-05	0.000423	CcSEcCtD
Tacrolimus—Ill-defined disorder—Doxorubicin—liver cancer	6.5e-05	0.000421	CcSEcCtD
Tacrolimus—Anaemia—Doxorubicin—liver cancer	6.48e-05	0.000419	CcSEcCtD
Tacrolimus—Myalgia—Epirubicin—liver cancer	6.45e-05	0.000417	CcSEcCtD
Tacrolimus—Arthralgia—Epirubicin—liver cancer	6.45e-05	0.000417	CcSEcCtD
Tacrolimus—Chest pain—Epirubicin—liver cancer	6.45e-05	0.000417	CcSEcCtD
Tacrolimus—Agitation—Doxorubicin—liver cancer	6.44e-05	0.000417	CcSEcCtD
Tacrolimus—Anxiety—Epirubicin—liver cancer	6.43e-05	0.000416	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	6.4e-05	0.000414	CcSEcCtD
Tacrolimus—Discomfort—Epirubicin—liver cancer	6.37e-05	0.000412	CcSEcCtD
Tacrolimus—Malaise—Doxorubicin—liver cancer	6.32e-05	0.000409	CcSEcCtD
Tacrolimus—Dry mouth—Epirubicin—liver cancer	6.31e-05	0.000408	CcSEcCtD
Tacrolimus—Vertigo—Doxorubicin—liver cancer	6.3e-05	0.000407	CcSEcCtD
Tacrolimus—Syncope—Doxorubicin—liver cancer	6.28e-05	0.000406	CcSEcCtD
Tacrolimus—Leukopenia—Doxorubicin—liver cancer	6.27e-05	0.000406	CcSEcCtD
Tacrolimus—Confusional state—Epirubicin—liver cancer	6.23e-05	0.000403	CcSEcCtD
Tacrolimus—Palpitations—Doxorubicin—liver cancer	6.19e-05	0.000401	CcSEcCtD
Tacrolimus—Oedema—Epirubicin—liver cancer	6.18e-05	0.0004	CcSEcCtD
Tacrolimus—Anaphylactic shock—Epirubicin—liver cancer	6.18e-05	0.0004	CcSEcCtD
Tacrolimus—Loss of consciousness—Doxorubicin—liver cancer	6.16e-05	0.000398	CcSEcCtD
Tacrolimus—Infection—Epirubicin—liver cancer	6.14e-05	0.000397	CcSEcCtD
Tacrolimus—Cough—Doxorubicin—liver cancer	6.12e-05	0.000395	CcSEcCtD
Tacrolimus—Shock—Epirubicin—liver cancer	6.08e-05	0.000393	CcSEcCtD
Tacrolimus—Convulsion—Doxorubicin—liver cancer	6.07e-05	0.000393	CcSEcCtD
Tacrolimus—Nervous system disorder—Epirubicin—liver cancer	6.06e-05	0.000392	CcSEcCtD
Tacrolimus—Thrombocytopenia—Epirubicin—liver cancer	6.05e-05	0.000391	CcSEcCtD
Tacrolimus—Hypertension—Doxorubicin—liver cancer	6.05e-05	0.000391	CcSEcCtD
Tacrolimus—Tachycardia—Epirubicin—liver cancer	6.03e-05	0.00039	CcSEcCtD
Tacrolimus—Skin disorder—Epirubicin—liver cancer	6e-05	0.000388	CcSEcCtD
Tacrolimus—Hyperhidrosis—Epirubicin—liver cancer	5.98e-05	0.000386	CcSEcCtD
Tacrolimus—Chest pain—Doxorubicin—liver cancer	5.97e-05	0.000386	CcSEcCtD
Tacrolimus—Arthralgia—Doxorubicin—liver cancer	5.97e-05	0.000386	CcSEcCtD
Tacrolimus—Myalgia—Doxorubicin—liver cancer	5.97e-05	0.000386	CcSEcCtD
Tacrolimus—Anxiety—Doxorubicin—liver cancer	5.95e-05	0.000385	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	5.93e-05	0.000383	CcSEcCtD
Tacrolimus—Discomfort—Doxorubicin—liver cancer	5.89e-05	0.000381	CcSEcCtD
Tacrolimus—Anorexia—Epirubicin—liver cancer	5.89e-05	0.000381	CcSEcCtD
Tacrolimus—Dry mouth—Doxorubicin—liver cancer	5.83e-05	0.000377	CcSEcCtD
Tacrolimus—Hypotension—Epirubicin—liver cancer	5.78e-05	0.000374	CcSEcCtD
Tacrolimus—Confusional state—Doxorubicin—liver cancer	5.77e-05	0.000373	CcSEcCtD
Tacrolimus—Oedema—Doxorubicin—liver cancer	5.72e-05	0.00037	CcSEcCtD
Tacrolimus—Anaphylactic shock—Doxorubicin—liver cancer	5.72e-05	0.00037	CcSEcCtD
Tacrolimus—Infection—Doxorubicin—liver cancer	5.68e-05	0.000367	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Epirubicin—liver cancer	5.63e-05	0.000364	CcSEcCtD
Tacrolimus—Shock—Doxorubicin—liver cancer	5.63e-05	0.000364	CcSEcCtD
Tacrolimus—Nervous system disorder—Doxorubicin—liver cancer	5.61e-05	0.000363	CcSEcCtD
Tacrolimus—Thrombocytopenia—Doxorubicin—liver cancer	5.6e-05	0.000362	CcSEcCtD
Tacrolimus—Insomnia—Epirubicin—liver cancer	5.59e-05	0.000362	CcSEcCtD
Tacrolimus—Tachycardia—Doxorubicin—liver cancer	5.58e-05	0.000361	CcSEcCtD
Tacrolimus—Skin disorder—Doxorubicin—liver cancer	5.56e-05	0.000359	CcSEcCtD
Tacrolimus—Paraesthesia—Epirubicin—liver cancer	5.55e-05	0.000359	CcSEcCtD
Tacrolimus—Hyperhidrosis—Doxorubicin—liver cancer	5.53e-05	0.000358	CcSEcCtD
Tacrolimus—Dyspnoea—Epirubicin—liver cancer	5.51e-05	0.000356	CcSEcCtD
Tacrolimus—Somnolence—Epirubicin—liver cancer	5.5e-05	0.000355	CcSEcCtD
Tacrolimus—Anorexia—Doxorubicin—liver cancer	5.45e-05	0.000353	CcSEcCtD
Tacrolimus—Dyspepsia—Epirubicin—liver cancer	5.44e-05	0.000352	CcSEcCtD
Tacrolimus—Decreased appetite—Epirubicin—liver cancer	5.37e-05	0.000348	CcSEcCtD
Tacrolimus—Hypotension—Doxorubicin—liver cancer	5.34e-05	0.000346	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Epirubicin—liver cancer	5.34e-05	0.000345	CcSEcCtD
Tacrolimus—Fatigue—Epirubicin—liver cancer	5.33e-05	0.000345	CcSEcCtD
Tacrolimus—Constipation—Epirubicin—liver cancer	5.29e-05	0.000342	CcSEcCtD
Tacrolimus—Pain—Epirubicin—liver cancer	5.29e-05	0.000342	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Doxorubicin—liver cancer	5.21e-05	0.000337	CcSEcCtD
Tacrolimus—Insomnia—Doxorubicin—liver cancer	5.17e-05	0.000335	CcSEcCtD
Tacrolimus—Paraesthesia—Doxorubicin—liver cancer	5.14e-05	0.000332	CcSEcCtD
Tacrolimus—Dyspnoea—Doxorubicin—liver cancer	5.1e-05	0.00033	CcSEcCtD
Tacrolimus—Feeling abnormal—Epirubicin—liver cancer	5.09e-05	0.000329	CcSEcCtD
Tacrolimus—Somnolence—Doxorubicin—liver cancer	5.08e-05	0.000329	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Epirubicin—liver cancer	5.05e-05	0.000327	CcSEcCtD
Tacrolimus—Dyspepsia—Doxorubicin—liver cancer	5.03e-05	0.000326	CcSEcCtD
Tacrolimus—Decreased appetite—Doxorubicin—liver cancer	4.97e-05	0.000322	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Doxorubicin—liver cancer	4.94e-05	0.000319	CcSEcCtD
Tacrolimus—Fatigue—Doxorubicin—liver cancer	4.93e-05	0.000319	CcSEcCtD
Tacrolimus—Urticaria—Epirubicin—liver cancer	4.91e-05	0.000318	CcSEcCtD
Tacrolimus—Pain—Doxorubicin—liver cancer	4.89e-05	0.000316	CcSEcCtD
Tacrolimus—Constipation—Doxorubicin—liver cancer	4.89e-05	0.000316	CcSEcCtD
Tacrolimus—Abdominal pain—Epirubicin—liver cancer	4.89e-05	0.000316	CcSEcCtD
Tacrolimus—Body temperature increased—Epirubicin—liver cancer	4.89e-05	0.000316	CcSEcCtD
Tacrolimus—Feeling abnormal—Doxorubicin—liver cancer	4.71e-05	0.000305	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Doxorubicin—liver cancer	4.68e-05	0.000302	CcSEcCtD
Tacrolimus—Hypersensitivity—Epirubicin—liver cancer	4.55e-05	0.000295	CcSEcCtD
Tacrolimus—Urticaria—Doxorubicin—liver cancer	4.54e-05	0.000294	CcSEcCtD
Tacrolimus—Abdominal pain—Doxorubicin—liver cancer	4.52e-05	0.000292	CcSEcCtD
Tacrolimus—Body temperature increased—Doxorubicin—liver cancer	4.52e-05	0.000292	CcSEcCtD
Tacrolimus—Asthenia—Epirubicin—liver cancer	4.43e-05	0.000287	CcSEcCtD
Tacrolimus—Pruritus—Epirubicin—liver cancer	4.37e-05	0.000283	CcSEcCtD
Tacrolimus—Diarrhoea—Epirubicin—liver cancer	4.23e-05	0.000274	CcSEcCtD
Tacrolimus—Hypersensitivity—Doxorubicin—liver cancer	4.21e-05	0.000273	CcSEcCtD
Tacrolimus—Asthenia—Doxorubicin—liver cancer	4.1e-05	0.000265	CcSEcCtD
Tacrolimus—Dizziness—Epirubicin—liver cancer	4.09e-05	0.000264	CcSEcCtD
Tacrolimus—Pruritus—Doxorubicin—liver cancer	4.05e-05	0.000262	CcSEcCtD
Tacrolimus—Vomiting—Epirubicin—liver cancer	3.93e-05	0.000254	CcSEcCtD
Tacrolimus—Diarrhoea—Doxorubicin—liver cancer	3.91e-05	0.000253	CcSEcCtD
Tacrolimus—Rash—Epirubicin—liver cancer	3.9e-05	0.000252	CcSEcCtD
Tacrolimus—Dermatitis—Epirubicin—liver cancer	3.89e-05	0.000252	CcSEcCtD
Tacrolimus—Headache—Epirubicin—liver cancer	3.87e-05	0.00025	CcSEcCtD
Tacrolimus—Dizziness—Doxorubicin—liver cancer	3.78e-05	0.000245	CcSEcCtD
Tacrolimus—Nausea—Epirubicin—liver cancer	3.67e-05	0.000237	CcSEcCtD
Tacrolimus—Vomiting—Doxorubicin—liver cancer	3.64e-05	0.000235	CcSEcCtD
Tacrolimus—Rash—Doxorubicin—liver cancer	3.61e-05	0.000233	CcSEcCtD
Tacrolimus—Dermatitis—Doxorubicin—liver cancer	3.6e-05	0.000233	CcSEcCtD
Tacrolimus—Headache—Doxorubicin—liver cancer	3.58e-05	0.000232	CcSEcCtD
Tacrolimus—Nausea—Doxorubicin—liver cancer	3.4e-05	0.00022	CcSEcCtD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	9.62e-06	8.9e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NAT2—liver cancer	9.59e-06	8.88e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—MYC—liver cancer	9.54e-06	8.83e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—RAF1—liver cancer	9.53e-06	8.82e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—TGFB1—liver cancer	9.52e-06	8.81e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GSTP1—liver cancer	9.45e-06	8.75e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—VEGFA—liver cancer	9.37e-06	8.67e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—HMOX1—liver cancer	9.32e-06	8.63e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PIK3CB—liver cancer	9.31e-06	8.61e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MTOR—liver cancer	9.31e-06	8.61e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PIK3CD—liver cancer	9.29e-06	8.6e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—STAT3—liver cancer	9.28e-06	8.59e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—IL6—liver cancer	9.25e-06	8.56e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—AKT1—liver cancer	9.25e-06	8.56e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—KRAS—liver cancer	9.22e-06	8.54e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ALDOB—liver cancer	9.19e-06	8.51e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—BRAF—liver cancer	9.17e-06	8.49e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CSF2—liver cancer	9.1e-06	8.42e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PSMA4—liver cancer	9.06e-06	8.38e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PSMD10—liver cancer	9.06e-06	8.38e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	9.01e-06	8.34e-05	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	8.97e-06	8.3e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—H2AFX—liver cancer	8.97e-06	8.3e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—KRAS—liver cancer	8.86e-06	8.2e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	8.83e-06	8.18e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—KRAS—liver cancer	8.82e-06	8.16e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GOT2—liver cancer	8.81e-06	8.15e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CRABP1—liver cancer	8.77e-06	8.12e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	8.77e-06	8.12e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—HPGDS—liver cancer	8.75e-06	8.1e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CDKN1B—liver cancer	8.73e-06	8.08e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CD—liver cancer	8.7e-06	8.06e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PPARG—liver cancer	8.7e-06	8.05e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GSTM1—liver cancer	8.68e-06	8.04e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MYC—liver cancer	8.62e-06	7.98e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—SERPINE1—liver cancer	8.61e-06	7.97e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TGFB1—liver cancer	8.6e-06	7.96e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CD—liver cancer	8.58e-06	7.94e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CASP3—liver cancer	8.56e-06	7.92e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL2—liver cancer	8.55e-06	7.91e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	8.55e-06	7.91e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—AKT1—liver cancer	8.54e-06	7.9e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SERPINE1—liver cancer	8.48e-06	7.85e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—PIK3CA—liver cancer	8.47e-06	7.84e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCND1—liver cancer	8.33e-06	7.71e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—JUN—liver cancer	8.32e-06	7.7e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—RAF1—liver cancer	8.29e-06	7.68e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYP2E1—liver cancer	8.28e-06	7.67e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CTNNB1—liver cancer	8.25e-06	7.64e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CYP1A1—liver cancer	8.23e-06	7.62e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—PIK3CA—liver cancer	8.14e-06	7.53e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TERT—liver cancer	8.11e-06	7.5e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PIK3CA—liver cancer	8.1e-06	7.5e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PIK3CB—liver cancer	8.1e-06	7.49e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MMP9—liver cancer	8.09e-06	7.49e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CDKN1A—liver cancer	8.06e-06	7.46e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KRAS—liver cancer	7.96e-06	7.37e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	7.92e-06	7.33e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MAPK8—liver cancer	7.87e-06	7.28e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HRAS—liver cancer	7.84e-06	7.26e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PSMA4—liver cancer	7.8e-06	7.22e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PSMD10—liver cancer	7.8e-06	7.22e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—RAF1—liver cancer	7.77e-06	7.19e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYCS—liver cancer	7.75e-06	7.17e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—MTHFR—liver cancer	7.67e-06	7.1e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—HPGDS—liver cancer	7.67e-06	7.1e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—RAF1—liver cancer	7.66e-06	7.09e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GOT1—liver cancer	7.6e-06	7.04e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GGT1—liver cancer	7.6e-06	7.04e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CDKN1B—liver cancer	7.6e-06	7.03e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GOT2—liver cancer	7.59e-06	7.02e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CB—liver cancer	7.59e-06	7.02e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PPARA—liver cancer	7.53e-06	6.97e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HRAS—liver cancer	7.53e-06	6.97e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—IL6—liver cancer	7.5e-06	6.95e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HRAS—liver cancer	7.5e-06	6.94e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CB—liver cancer	7.48e-06	6.92e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL2—liver cancer	7.44e-06	6.88e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KDR—liver cancer	7.42e-06	6.86e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MAPK14—liver cancer	7.37e-06	6.82e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CPT1B—liver cancer	7.33e-06	6.79e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GLUL—liver cancer	7.33e-06	6.79e-05	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—AKT1—liver cancer	7.33e-06	6.78e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PIK3CA—liver cancer	7.32e-06	6.77e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—VEGFA—liver cancer	7.26e-06	6.72e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—JUN—liver cancer	7.23e-06	6.69e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ESR1—liver cancer	7.23e-06	6.69e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	7.22e-06	6.68e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—STAT3—liver cancer	7.19e-06	6.66e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CTNNB1—liver cancer	7.18e-06	6.64e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—IL6—liver cancer	7.17e-06	6.64e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—F2—liver cancer	7.14e-06	6.61e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP2E1—liver cancer	7.13e-06	6.6e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—liver cancer	7.08e-06	6.55e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NR1H4—liver cancer	7.07e-06	6.54e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CDKN1B—liver cancer	7.02e-06	6.49e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CDKN1A—liver cancer	7.01e-06	6.49e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IL2—liver cancer	6.97e-06	6.45e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTA3—liver cancer	6.95e-06	6.43e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—AKT1—liver cancer	6.92e-06	6.41e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	6.91e-06	6.39e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—MAPK8—liver cancer	6.84e-06	6.33e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PSMD10—liver cancer	6.83e-06	6.33e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PSMA4—liver cancer	6.83e-06	6.33e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—APC—liver cancer	6.83e-06	6.32e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CG—liver cancer	6.83e-06	6.32e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTP1—liver cancer	6.83e-06	6.32e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HRAS—liver cancer	6.77e-06	6.27e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—HMOX1—liver cancer	6.74e-06	6.24e-05	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—RAF1—liver cancer	6.73e-06	6.23e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MYC—liver cancer	6.68e-06	6.19e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYCS—liver cancer	6.67e-06	6.18e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TGFB1—liver cancer	6.67e-06	6.17e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GOT2—liver cancer	6.65e-06	6.15e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—AKT1—liver cancer	6.65e-06	6.15e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CTNNB1—liver cancer	6.63e-06	6.13e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—AKT1—liver cancer	6.62e-06	6.13e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GGT1—liver cancer	6.55e-06	6.06e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GOT1—liver cancer	6.55e-06	6.06e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	6.52e-06	6.03e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL6—liver cancer	6.48e-06	6e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CDKN1A—liver cancer	6.47e-06	5.99e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CG—liver cancer	6.45e-06	5.97e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—BRAF—liver cancer	6.42e-06	5.94e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTA4—liver cancer	6.36e-06	5.88e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTM1—liver cancer	6.28e-06	5.81e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—STAT3—liver cancer	6.26e-06	5.79e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP2E1—liver cancer	6.25e-06	5.79e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PPARG—liver cancer	6.22e-06	5.76e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTA2—liver cancer	6.19e-06	5.73e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KRAS—liver cancer	6.18e-06	5.72e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CD—liver cancer	6.01e-06	5.56e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AKT1—liver cancer	5.98e-06	5.53e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTA1—liver cancer	5.98e-06	5.53e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYP1A1—liver cancer	5.95e-06	5.51e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SERPINE1—liver cancer	5.94e-06	5.5e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—VEGFA—liver cancer	5.92e-06	5.48e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NAT2—liver cancer	5.91e-06	5.47e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	5.89e-06	5.46e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTP1—liver cancer	5.88e-06	5.45e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYCS—liver cancer	5.85e-06	5.41e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—HMOX1—liver cancer	5.8e-06	5.37e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—STAT3—liver cancer	5.78e-06	5.35e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GGT1—liver cancer	5.74e-06	5.31e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GOT1—liver cancer	5.74e-06	5.31e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PIK3CA—liver cancer	5.67e-06	5.25e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CD—liver cancer	5.67e-06	5.25e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ALDOB—liver cancer	5.67e-06	5.24e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ALB—liver cancer	5.6e-06	5.18e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—MTHFR—liver cancer	5.55e-06	5.13e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—liver cancer	5.49e-06	5.08e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PPARA—liver cancer	5.44e-06	5.04e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TGFB1—liver cancer	5.43e-06	5.03e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTM1—liver cancer	5.41e-06	5e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CRABP1—liver cancer	5.4e-06	5e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KRAS—liver cancer	5.37e-06	4.97e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MYC—liver cancer	5.37e-06	4.97e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RAF1—liver cancer	5.36e-06	4.96e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TGFB1—liver cancer	5.35e-06	4.96e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HRAS—liver cancer	5.25e-06	4.86e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CB—liver cancer	5.23e-06	4.85e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTP1—liver cancer	5.15e-06	4.77e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP1A1—liver cancer	5.13e-06	4.74e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—HMOX1—liver cancer	5.08e-06	4.71e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—KRAS—liver cancer	5.03e-06	4.66e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL6—liver cancer	5.02e-06	4.65e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KRAS—liver cancer	4.96e-06	4.59e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CB—liver cancer	4.94e-06	4.57e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PIK3CA—liver cancer	4.94e-06	4.57e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CDKN1B—liver cancer	4.91e-06	4.55e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CASP3—liver cancer	4.81e-06	4.46e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL2—liver cancer	4.81e-06	4.45e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—MTHFR—liver cancer	4.78e-06	4.42e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTM1—liver cancer	4.74e-06	4.38e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HPGDS—liver cancer	4.72e-06	4.37e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PPARA—liver cancer	4.69e-06	4.34e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCND1—liver cancer	4.69e-06	4.34e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—JUN—liver cancer	4.68e-06	4.33e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CG—liver cancer	4.66e-06	4.31e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CTNNB1—liver cancer	4.64e-06	4.3e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AKT1—liver cancer	4.64e-06	4.29e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CA—liver cancer	4.62e-06	4.28e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HRAS—liver cancer	4.57e-06	4.23e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CA—liver cancer	4.56e-06	4.22e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MMP9—liver cancer	4.55e-06	4.21e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CDKN1A—liver cancer	4.53e-06	4.2e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PPARG—liver cancer	4.5e-06	4.16e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP1A1—liver cancer	4.49e-06	4.16e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—liver cancer	4.47e-06	4.14e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MAPK8—liver cancer	4.42e-06	4.1e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL6—liver cancer	4.37e-06	4.05e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—HRAS—liver cancer	4.28e-06	3.96e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HRAS—liver cancer	4.22e-06	3.9e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.21e-06	3.9e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PSMD10—liver cancer	4.21e-06	3.9e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PSMA4—liver cancer	4.21e-06	3.9e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—MTHFR—liver cancer	4.19e-06	3.87e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PPARA—liver cancer	4.11e-06	3.8e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CD—liver cancer	4.1e-06	3.79e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GOT2—liver cancer	4.1e-06	3.79e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VEGFA—liver cancer	4.09e-06	3.78e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—STAT3—liver cancer	4.05e-06	3.74e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ALB—liver cancer	4.05e-06	3.74e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—IL6—liver cancer	4.04e-06	3.73e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—AKT1—liver cancer	4.03e-06	3.73e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CG—liver cancer	4.01e-06	3.72e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PPARG—liver cancer	3.87e-06	3.59e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP2E1—liver cancer	3.85e-06	3.56e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—AKT1—liver cancer	3.78e-06	3.5e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MYC—liver cancer	3.76e-06	3.48e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TGFB1—liver cancer	3.75e-06	3.47e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—AKT1—liver cancer	3.72e-06	3.45e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYCS—liver cancer	3.6e-06	3.33e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CB—liver cancer	3.57e-06	3.31e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GGT1—liver cancer	3.54e-06	3.27e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GOT1—liver cancer	3.54e-06	3.27e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CD—liver cancer	3.53e-06	3.27e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CG—liver cancer	3.52e-06	3.26e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KRAS—liver cancer	3.47e-06	3.21e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PPARG—liver cancer	3.39e-06	3.14e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CA—liver cancer	3.19e-06	2.95e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTP1—liver cancer	3.18e-06	2.94e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HMOX1—liver cancer	3.13e-06	2.9e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CD—liver cancer	3.09e-06	2.86e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—liver cancer	3.09e-06	2.86e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CB—liver cancer	3.08e-06	2.85e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ALB—liver cancer	3.05e-06	2.83e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CA—liver cancer	3.01e-06	2.79e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HRAS—liver cancer	2.95e-06	2.73e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTM1—liver cancer	2.92e-06	2.7e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL6—liver cancer	2.83e-06	2.62e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP1A1—liver cancer	2.77e-06	2.56e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CB—liver cancer	2.7e-06	2.49e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKT1—liver cancer	2.61e-06	2.41e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—MTHFR—liver cancer	2.58e-06	2.39e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PPARA—liver cancer	2.53e-06	2.34e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AKT1—liver cancer	2.46e-06	2.28e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CA—liver cancer	2.18e-06	2.02e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CG—liver cancer	2.17e-06	2.01e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PPARG—liver cancer	2.09e-06	1.94e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CD—liver cancer	1.91e-06	1.76e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ALB—liver cancer	1.88e-06	1.74e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CA—liver cancer	1.88e-06	1.74e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AKT1—liver cancer	1.78e-06	1.65e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CB—liver cancer	1.66e-06	1.54e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CA—liver cancer	1.64e-06	1.52e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AKT1—liver cancer	1.53e-06	1.42e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AKT1—liver cancer	1.34e-06	1.24e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CA—liver cancer	1.01e-06	9.37e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKT1—liver cancer	8.27e-07	7.65e-06	CbGpPWpGaD
